Cytokine signal regulation and autoimmune disorders

References

• Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994; 76: 253–262
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167–2179
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T, Yoshizaki Y. Anti-cytokine therapy in autoimmune diseases. Intern Med 1999; 38: 178–182
   PubMed Web of Science ®Google Scholar
• Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283–350
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/INF β2) receptor. Science 1988; 241: 825–828
   PubMed Web of Science ®Google Scholar
• Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573–581
   PubMed Web of Science ®Google Scholar
• Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149–1157
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993; 53: 851–856
   PubMed Web of Science ®Google Scholar
• Harris ED, Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277–1289
   PubMed Web of Science ®Google Scholar
• Cush JJ, Lipsky PE. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum 1988; 31: 1230–1238
   PubMed Web of Science ®Google Scholar
• Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797–1801
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Sato K, Hashimoto J, Kohsaka H, Yamamoto K, Goto M, Inoue K, Matsuda T, Hirano T, Kishimoto T, et al. Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. Clin Immunol Immunopathol 1989; 52: 238–247
   PubMedGoogle Scholar
• Harigai M, Hara M, Kitani A, Norioka K, Hirose T, Hirose W, Suzuki K, Kawakami M, Masuda K, Shinmei M, et al. Interleukin 1 and tumor necrosis factor-alpha synergistically increase the production of interleukin 6 in human synovial fibroblast. J Clin Lab Immunol 1991; 34: 107–113
   PubMedGoogle Scholar
• Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73–76
   PubMed Web of Science ®Google Scholar
• Noma T, Mizuta T, Rosen A, Hirano T, Kishimoto T, Honjo T. Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett 1987; 15: 249–253
   PubMed Web of Science ®Google Scholar
• Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141: 1543–1549
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878–4882
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Tagoh H, Monden M, Kishimoto S, Hirano T, Kishimoto T. Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 1989; 50: 399–401
   PubMedGoogle Scholar
• Isshiki H, Akira S, Sugita T, Nishio Y, Hashimoto S, Pawlowski T, Suematsu S, Kishimoto T. Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: Possible involvement of NF-IL6 in acute phase protein gene expression. N Biol 1991; 3: 63–70
   PubMedGoogle Scholar
• Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 1989; 86: 5953–5957
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74: 1241–1244
   PubMed Web of Science ®Google Scholar
• Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1521–1529
   PubMed Web of Science ®Google Scholar
• Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993; 90: 11924–11928
   PubMed Web of Science ®Google Scholar
• Takai Y, Seki N, Senoh H, Yokota T, Lee F, Hamaoka T, Fujiwara H. Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. Arthritis Rheum 1989; 32: 594–600
   PubMed Web of Science ®Google Scholar
• Sugita T, Furukawa O, Ueno M, Murakami T, Takata I, Tosa T. Enhanced expression of interleukin 6 in rat and murine arthritis models. Int J Immunopharmacol 1993; 15: 469–476
   PubMed Web of Science ®Google Scholar
• Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, Takeda Y, Ohsugi Y. Blockage of Interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998; 41: 2117–2121
   PubMed Web of Science ®Google Scholar
• Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, Katada Y, Yoshizaki K, Suemura M, Kishimoto T. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999; 42: 1635–1643
   PubMed Web of Science ®Google Scholar
• Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784–9788
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95: 237–243
   PubMed Web of Science ®Google Scholar
• Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 1998; 95: 8222–8226
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Tosu M, Yoshida E, Takiguchi M, Sato K, Kitajima I, Nishioka K, Yamamoto K, Takeda T, Hatanaka M, et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 1991; 253: 1026–1028
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Saijo S, Kioka Y, Nakayama-Yamada J, Itagaki K, Tosu M, Asano M, Kanai Y, Kakimoto K. Autoimmunity induction by HTLV-1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol 1995; 155: 1588–1598
   PubMed Web of Science ®Google Scholar
• Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 2002; 46: 533–544
   PubMed Web of Science ®Google Scholar
• Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313–320
   PubMed Web of Science ®Google Scholar
• Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003; 100: 5986–5990
   PubMed Web of Science ®Google Scholar
• Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, Kobayashi H, Park SJ, Saeki Y, Kitamura Y, Hirano T. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002; 196: 979–990
   PubMed Web of Science ®Google Scholar
• Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, Ochi T. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532–2542
   PubMed Web of Science ®Google Scholar
• Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, Takahi K, Nakase T, Kaneda Y, Yoshikawa H, Ochi T. Transcription factor decoy for NF kappa B inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000; 39: 749–757
   PubMed Web of Science ®Google Scholar
• Hanada T, Yoshida H, Kato S, Tanaka K, Masutani K, Tsukada J, Nomura Y, Mimata H, Kubo M, Yoshimura A. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003; 19: 437–450
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Tsutsui H, Xinshou O, Tokumoto M, Watanabe D, Shima Y, Yoshimoto T, Hirakata H, Kawase I, Nakanishi K, Kishimoto T, Naka T. Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol 2004; 16: 303–314
   PubMed Web of Science ®Google Scholar
• Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Investig 2001; 108: 1781–1788
   PubMed Web of Science ®Google Scholar
• Mihara M, Kotoh M, Nishimoto N, Oda Y, Kumagai E, Takagi N, Tsunemi K, Ohsugi Y, Kishimoto T, Yoshizaki K, Takeda Y. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 2001; 98: 319–326
   PubMed Web of Science ®Google Scholar
• Matsuno H, Sawai T, Nezuka T, Uzuki M, Tsuji H, Nishimoto N, Yoshizaki K. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody. Arthritis Rheum 1998; 41: 2014–2021
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 antibody treatment in rheumatic disease. Ann Rheum Dis 2000; 59: i21–i27
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et al. Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody. Arthritis Rheum 2002; 46: 3143–3150
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Takagi N, et al. Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis -Phase I/II clinical study. J Rheumatol 2003; 30: 1426–1435
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761–1769
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 1997; 337: 1029–1035
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, Arima N, Oriishi T, Harada K, Fujisaki K, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 1991; 50: 104–111
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, Harada K, Tateishi H, Nishiyama T, Tanikawa K. Soluble interleukin-6 receptors in inflammatory bowel disease: Relation to circulating interleukin-6. Gut 1995; 36: 45–49
   PubMed Web of Science ®Google Scholar
• Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig Dis Sci 1998; 43: 2071–2079
   PubMed Web of Science ®Google Scholar
• Funakoshi K, Sugimura K, Anezaki K, Bannai H, Ishizuka K, Asakura H. Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion 1998; 59: 73–78
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Sata M, Tanikawa K. Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn 1991; 26: 20–28
   PubMedGoogle Scholar
• Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, Ina K, Kanayama K, Ando T, Matsuura T, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 1995; 40: 949–959
   PubMed Web of Science ®Google Scholar
• Hosokawa T, Kusugami K, Ina K, Ando T, Shinoda M, Imada A, Ohsuga M, Sakai T, Matsuura T, Ito K, Kaneshiro K. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999; 14: 987–996
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583–588
   PubMed Web of Science ®Google Scholar
• Ito H, Hirotani T, Yamamoto M, Ogawa H, Kishimoto T. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J Gastroenterol 2002; 37(Suppl 14)56–61
   PubMedGoogle Scholar
• Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471–481
   PubMed Web of Science ®Google Scholar
• Kanai T, Watanabe M, Okazawa A, Sato T, Hibi T. Interleukin-18 and Crohn's disease. Digestion 2001; 63(Suppl. 1)37–42
   PubMedGoogle Scholar
• Kanai T, Watanabe M, Okazawa A, Sato T, Yamazaki M, Okamoto S, Ishii H, Totsuka T, Iiyama R, Okamoto R, Ikeda M, Kurimoto M, Takeda K, Akira S, Hibi T. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001; 121: 875–888
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989–996
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991–1994
   PubMedGoogle Scholar
• Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 421–426
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol 1998; 25: 203–207
   PubMed Web of Science ®Google Scholar
• Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003; 15: 581–586
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818–825
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002; 46: 3388–3389
   PubMed Web of Science ®Google Scholar